Monday, August 11, 2014

Hatch-Waxman action between Teva and Dr. Reddy's over 40 mg Copaxone

Teva Pharmaceutical Industries intends to file a Hatch-Waxman infringement law suit against Dr Reddy's Laboratories related to Reddy's paragraph IV filing as to the patents of Copaxone (glatiramer acetate) injection 40mg/mL.


Copaxone is the subject of the pending Supreme Court case between Teva and Sandoz involving a dispute over claim language asserting molecular weight. The United States Supreme Court rejected Teva's application for an injunction seeking to prevent launch of a generic version of Copaxone involving Natco Pharma.


Post a Comment

<< Home